Fluidigm Files Preliminary Proxy Statement In Connection With Proposed Strategic Capital Infusion From Casdin Capital And Viking Global Investors

Fluidigm Corporation (NASDAQ:FLDM) today filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy statement for a special meeting of stockholders (the “Special Meeting”) at which Fluidigm stockholders will have the opportunity to consider and vote upon various items related to the proposed and previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (“Casdin”) and Viking Global Investors LP (“Viking”). In connection with filing the preliminary proxy statement, Fluidigm also filed a strategic capital overview presentation. Both the preliminary proxy statement and strategic capital overview presentation can be found at www.sec.gov.

As previously announced on January 24, 2022, assuming stockholder approval and satisfaction of closing conditions, Fluidigm expects to receive an aggregate $250 million investment, inclusive of $25 million previously raised in the form of term loans, from Casdin and Viking, which will significantly advance the Company’s mission through new organic and inorganic growth initiatives while optimizing its cost structure. Upon the closing of the investment, Fluidigm will change its name to Standard BioTools Inc., better reflecting its ambitions to become an essential solutions partner to the life science industry focused on the highest growth areas of biological discovery and development.
        
Fluidigm’s preliminary proxy statement and strategic capital overview presentation can be found at www.sec.gov. When available, the Company will file its definitive proxy statement with the SEC, and expects to mail its definitive proxy statement and a proxy card in the coming weeks to all stockholders eligible to vote at the Special Meeting. The Fluidigm Board notes that stockholders are not required to take any action at this time.